Aptus Pharma Ltd

📊 Aptus Pharma FY2026 Results: Revenue at ₹32.2 Cr, Announces 3:2 Bonus Share Issue

• Revenue from operations for FY ended March 31, 2026: ₹3,219.71 lakhs

• Net profit after tax: ₹461.99 lakhs

• Earnings per share (EPS): ₹7.78 (basic and diluted)

• Bonus share issue announced in ratio of 3:2 (three bonus shares for every two existing equity shares)

• Total equity and liabilities/assets as of March 31, 2026: ₹4,353.48 lakhs

• Cash and cash equivalents decreased to ₹102.71 lakhs from ₹521.43 lakhs in the previous year

• IPO proceeds fully utilized: ₹162.95 lakhs for capital expenditure, ₹800 lakhs for working capital, ₹191.05 lakhs for general corporate purposes